Skip to main content
Clinical Trials/KCT0003963
KCT0003963
Not yet recruiting
未知

Prospective cohort study for genomic evaluation in patients with diffuse large B cell lymphoma after first relapse/progression

Samsung Medical Center0 sites200 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Samsung Medical Center
Enrollment
200
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with histopathologically confirmed DLBCL
  • 2\.Patients diagnosed with DLBCL who relapsed or were refractory to first\-line treatment with rituximab\-based immunotherapy
  • 3\.Patients available for genomic analysis of tissues both at diagnosis (paraffin\-embedded and stored) and at relapse (paraffin\-embedded)
  • 4\.Patients aged \=18 years
  • 5\.Patients who provide written informed consent for participation in the prospective cohort study
  • 6\.Patients who provide written informed consent to peripheral blood collection and genetic testing of human tissues

Exclusion Criteria

  • 1\.Patients who have no lymphoid malignancy, e.g. myeloid leukemia
  • 2\.Patients with any of the following lymphoid malignancies:
  • 1\)Plasma cell dyscrasia, amyloidosis
  • 2\)Hodgkin lymphoma
  • 3\)Subtypes of B cell non\-Hodgkin lymphoma, other than DLBCL
  • 4\)T or NK cell non\-Hodgkin lymphoma
  • 5\)Other diseases in the WHO classification of lymphoid malignancies
  • 3\.Patients who have experienced a relapse before
  • 4\.Patients with insufficient or no tissue sample at diagnosis for genomic analysis
  • 5\.Patients who do not understand or provide written informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials